TGTX Stock Analysis: Buy, Sell, or Hold?
TGTX - TG Therapeutics, Inc.
$46.17
-5.86 (-11.26%)
▼
5d:
-17.18%
30d:
-13.39%
90d:
+36.4%
WAIT
LOW Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 03, 2026
0d
Smart Money Accumulation
None View Scanner →
Strength: 6.5/10
Get Alerted When TGTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: TGTX is down 17.2% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: TGTX is down 17.2% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$100.95
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$62.68
26.3% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 15.8x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: TGTX is currently trading at $46.17, which is considered oversold relative to its 30-day fair value range of $52.43 to $57.05. From a valuation perspective, the stock is trading at a discount (Forward PE: 14.1) compared to its historical average (15.8). Remarkably, the market is currently pricing in an annual earnings decline of 3.7% over the next few years. This pessimistic expectation contrasts with the company's recent 300% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, TGTX is in a strong uptrend. The price is currently testing key support at $45.82. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 11.3% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $68.43 (+48.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, TGTX is in a strong uptrend. The price is currently testing key support at $45.82. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 11.3% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $68.43 (+48.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$52.43 -
$57.05
Company Quality Score
60/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
74.8%
Protect Your Profits
Holding TGTX? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-11.3%)
- BULLISH: Trading 48.2% below Wall St target ($68.43)
- WARNING: Recommendation downgraded due to -17.2% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$52.43 -
$57.05
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$45.82
Resistance Level
$57.58
Current Trend
Strong Uptrend
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
14.07
Wall Street Target
$68.43
(+48.2%)
Revenue Growth (YoY)
69.6%
Earnings Growth (YoY)
300.0%
Profit Margin
66.0%
Valuation Discount vs History
-3.7% cheaper
PE vs Historical
14.1 vs 15.8
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-3.7%
(market-implied from PE analysis)
1-Year Target
$44.46
(-4%)
2-Year Target
$42.82
(-7%)
3-Year Target
$41.23
(-11%)
3-Yr Target (if PE normalizes)
(PE: 14→16)
$46.30
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.7, Growth: 108.7%)
$229.56
(+397%)
Base:
(SPY PE: 14.1, Growth: 108.7%)
$155.82
(+238%)
Bear:
(PE: 12.0, Growth: 108.7%)
$132.45
(+187%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (18x PE), but valuation improves significantly next year (14x PE) as earnings recover.
Trailing PE: 18.19 | Current EPS (TTM): $2.86
Bull Case
$65.66
(+42%)
Analyst growth 14.7%, PE expands to 20.0
Base Case
$59.69
(+29%)
Market implied 14.7%, PE stable at 18.2
Bear Case
$35.38
(-23%)
Severe decline -20.0%, PE contracts to 15.5
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 14.1 to 15.8
Stabilization Target:
$51.84
(+12.3%)
PE Expansion Potential:
+12.3%
Share & Embed Analysis
Last updated: August 03, 2026 8:54 PM ET
Data refreshes hourly during market hours. Next update: 9:54 PM
Data refreshes hourly during market hours. Next update: 9:54 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TGTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$26 | 50 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 49 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1080 | 57 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$52 | 54 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$127 | 59 HOLD |
Advanced TGTX Option Strategies
Professional options setups generated by AI based on today's TGTX price and gamma walls.
